From 1991 to 1996, CMV infection had been diagnosed in 632/1971 (32%) AIDS patients in our unit, 65% of them having retinitis. After AIDS diagnosis, the risk of CMV visceral manifestations was 16% at 1 year, 34% at 2 years, and 46% at 3 years. The risk of CMV has increased over time owing to both a longer survival induced by antiretroviral therapies and a better management of opportunistic infections in patients with a persistent low immune status. In a natural history study of 1002 patients the probability of CMV disease at 2 years was 21.4% for patients with levels of CD4 below 100 x 106/1 compared with 10-3% for those with CD4 greater than 100 x 106/1.1 Interestingly "the protease inhibitors era" which started in the USA and some European countries, in spring 1996 has dramatically changed the Foscamet is a pyrophosphate analogue which directly inhibits viral DNA polymerase without the need for prior phosphorylation to be active. It has a broad antiviral spectrum7 and is active against ganciclovir resistant CMV strains, herpes simplex (HSV) including aciclovir resistant HSV strains, and varicella zoster virus (VZV). It has potential activity against HHV8, the putative agent for Kaposi's sarcoma. 8 Foscarnet is given by intravenous daily infusion-90 mg/kg twice daily as induction therapy for 2 to 3 weeks, and 90-120 mg/kg/day as one daily infusion in maintenance therapy.9 10 Concomitant hydration with isotonic saline has considerably reduced the incidence of renal toxicity which represents the major adverse event of this therapy."' Evaluation of oral hydration is ongoing but preliminary results during induction therapy suggest that oral hydration can be safely used instead of intravenous hydration.'2 Other side effects include hypocalcaemia, genital ulcerations, and nausea/vomiting.
Foscarnet offers the advantage of being active on ganciclovir resistant strains, and it has an anti-HIV activity with an average 03 to 0.5 log reduction in HIV RNA plasma viral load'3; it also has a synergistic activity with nucleoside analogues such as zidovudine which may account for the survival benefit in comparison with ganciclovir (12-6 months versus 8.5 months; p = 0 007) observed in the SOCA trial. '4 Ganciclovir Ganciclovir is a nucleoside analogue which requires to be phosphorylated in CMV infected cells. Mutations of thymidine kinase as modifications of UL97 gene are main causes of ganciclovir resistance which develops over time during prolonged ganciclovir treatment. Mutation on DNA polymerase has also been reported with cross resistance with cidofovir. '5 16 Ganciclovir exists as two formulations: intravenous ganciclovir represents the standard treatment given as 5 mg/kg twice daily as induction therapy for 14 to 21 days, and 5 mg/kg one daily as maintenance treatment; oral ganciclovir is hampered by a low bioavailability (5%) leading to use of a high daily dosage (3 g/day given as a 1 g regimen three times daily). Its lesser efficacy than intravenous formulation gives a median time of progression to CMV retinitis measured by retinal photographs of about 55 days compared with 65 days with the intravenous formulation. This difference was not statistically significant, but what was significant was the progression rate when observed by funduscopic examination (75 days with oral ganciclovir and 100 days with intravenous ganciclovir17 18). The use of oral ganciclovir is limited to maintenance therapy and to primary prophylaxis of CMV retinitis.
The most limiting adverse reactions for ganciclovir are haematotoxicity, mainly neutropenia and anaemia. Growth factors such as G-CSF/GM-CSF may be used in patients with severe neutropenia when a switch to foscarnet is not possible.
Development of resistance of CMV to ganciclovir is correlated with the duration of drug exposure. In a study of 16 viral isolates from patients treated for more than a month, the percentages of both high level and low level ganciclovir resistance were respectively 19% and 81 % when treatment was less than 9 months and 64% and 36% when treatment was longer than a year. Most of this resistance was correlated with the appearance of a mutation within the UL97 gene which encodes for the CMV specific transferase. Furthermore, high level ganciclovir resistance has a strong correlation with cidofovir resistance; some isolates of highly ganciclovir resistant strains might develop foscarnet resistance more quickly than expected.'9 In brief, these data mean that the development of viral resistance is correlated with antiviral treatment which allows persistent viral growth; ganciclovir resistance is common over long term treatment and may induce cross resistance to other drugs. Cidofovir Cidofovir (Vistide HPMPC) is a nucleotide analogue of cytosine with potent in vitro and in vivo activity of prolonged duration against a broad spectrum of herpes viruses including CMV and herpes simplex type 1 and 2, VZV, and Epstein-Barr virus (EBV). Unlike aciclovir or ganciclovir which require intracellular activation by viral encoded enzyme, conversion of cidofovir to cidofovir diphosphate, which is the active cellular metabolite, is performed by host cellular enzymes and is therefore independent of viral infection. The diphosphate has a long intracellular half life (17-65 hours) which results in prolonged antiviral effects of cidofovir. The major dose limiting toxicity is dose dependent nephrotoxicity leading to degeneration and necrosis of renal proximal tubule cells. Concomitant administration of probenecid is thought to reduce the toxicity by competing with cidofovir for uptake at the surface of the tubule thereby minimising cidofovir toxicity, although the pharmacokinetics is complicated and probably irrelevant at the lower dose of 3 mg/kg.
Cidofovir is administered in acute therapy as 5 mg/kg once a week for 2 weeks, followed by 5 mg/kg every 2 weeks as maintenance therapy, and prehydration with a 1 litre intravenous infusion of normal saline. Oral probenecid is given as a 2 g dose in the 3 hours before infusion, and 1 g, 2 and 8 hours after infusion.
When there is concomitant use of probenecid, zidovudine clearance decreases by 50%, so patients should be advised to decrease by 50% or interrupt zidovudine use on each day of cidofovir injection.
In a prospective controlled trial20 comparing immediate treatmnent with cidofovir (5 mg/kg weekly) with other treatments in non-sight threatening retinitis, the median time to progression of retinitis was 22 days compared with 120 days for the immediate treatment group (p < 0-0001). In this study, proteinuria occurred in 12% of patients, elevation of serum creatinine in 5% of patients; overall, 24% of patients discontinued treatment because of nephrotoxicity. Renal toxicity may not always be reversible. Early immunological symptoms of renal tubular necrosis such as hypophosphoraemia, hypokalaemia, and hypoglycaemia should be looked for. Patients with pre-existing renal dysfunction or mild proteinuria should avoid the use of cidofovir. After two or three cidofovir treatments 50-60% of patients had evidence of mild to moderate probenecid reactions, most commonly consisting of fever, chills, and rash.202' Cidofovir is currently licensed for the treatment of CMV retinitis and in Europe for patients failing standard therapy.
Although cidofovir is not an easy drug to manage, because of its potential side effects, the major advantage is the possibility for maintenance therapy to be given as one injection every 2 weeks. The impact on quality of life, especially as the patient does not need an indwelling central catheter, compared with daily administrations of foscarnet or ganciclovir is of importance. Lobucavir Lobucavir is a guanine nucleoside analogue with a broad spectrum antiviral activity against CMV, herpes simplex, and VZV; interestingly, the compound has also in vitro inhibiting activity on HIV replication in monocytemacrophage cell line, probably through inhibition of reverse transcriptase activity and it appears also to have in vitro activity against hepatitis B. Bioavailability following oral administration of lobucavir varies around 50%.22 23 Phase I/II studies of lobucavir have demonstrated an in vivo activity on CMV treatment in urine or semen. Phase III trials in treatment and prophylaxis of retinitis are planned. Adefovir Adefovir (PMEA) is a nucleotide analogue of adenosine with activity on a broad spectrum of retro and herpes viruses including HIV and CMV.2425 Phosphorylation of PMEA in cells to PMEApp is independent of virus infection; thus, PMEA may prime uninfected cells to resist viral infection when subsequently infected. Because of low oral bioavailability, several compounds have been synthesised to circumvent this problem; among them adefovir dipivoxil (bis POM PMEA) has an advantageous pharmacokinetic profile. Preliminary data suggest that adefovir leads to a 0.6 log,0 reduction in HIV viral load and 0.3 to 0.7 logl0 decrease in CMV viral load when studied in a small number of patients. A large phase III placebo controlled trial with adefovir both as anti-HIV and prophylactic drug is being planned.
Prodrug ofganciclovir
Valganciclovir is the valine ester of ganciclovir, a prodrug that is de-esterified to produce ganciclovir in the peripheral blood A dose ranging study26 in 32 The rationale for using local therapy is to administer a specific treatment at the site of the infectious process, thus avoiding all the complications of systemic therapy. Several local treatment strategies have been used over time.
Intravitreal injections
Ganciclovir has been the drug used most often. Intravitreal injections with ganciclovir include one injection twice weekly as induction therapy followed by one injection weekly as maintenance therapy (400,g ganciclovir per injection). Although no randomised studies have compared intravitreal injections with intravenous ganciclovir, results demonstrate a similar efficacy of the two treatments for progression in the affected eye.
Intravitrealfoscarnet
There have been fewer experiences with intravitreal injections of foscarnet which is not easy to infuse given the large volume needed.
Intravitreal implants An important approach has been the concept of permanent intravitreal devices to deliver ganciclovir continuously over several months (up to 6-8 months). These intraocular ganciclovir implants have been evaluated in two randomised studies in comparison with intravenous ganciclovir. Better control of CMV retinitis was obtained with ganciclovir implants (2 gg/h) with a median time of progression of 180-200 days; a higher risk of extraocular disease (15%) was usually observed and the development of CMV retinitis in the fellow eye, with 50% of cases within 6 months. 2728 The main advantages of local therapy, particularly with intraocular ganciclovir implants, is a better control of CMV retinitis, compared with systemic intravenous infusion and a major improvement in quality of life avoiding any systemic potentially toxic therapy. However, the major drawback of this local therapeutic strategy is to treat only the eye affected by CMV and not the whole CMV pathological process, with the consequence of development of retinitis in the fellow eye or occurrence of extraocular CMV complications. Other specific complications of local therapy include conjunctival bleeding and infection; retinal detachment, a common complication in the long term CMV retinal process, might be facilitated by regular injections.
MANAGEMENT OF CMV RETINITIS THERAPY
One particular feature of CMV retinitis is its high tendency to relapse. Because of an overall longer survival, patients may experience several acute CMV retinitis episodes. Therefore, it is important to adapt to each individual clinical situation and give the optimal therapy. The acute treatment of CMV retinitis necrosis optimally consists of 2 or 3 weeks of intravenous treatment. The choice between foscamet and ganciclovir will depend on various factors such as concurrent or previous anti-CMV treatment, renal function, the polymorphonuclear cell count and haemoglobin level, the current clinical and social status of the patient, and any concomitant antineoplastic chemotherapy.
Reasons to choose ganciclovir are ease of administration, and a good clinical tolerance, whereas reasons to prefer foscarnet are a proved or possible resistant CMV strain to ganciclovir, neutropenia or low haemoglobin level, a specific anti-HIV effect that may complement antiretroviral therapy, and the absence of need for expensive leucocyte growth factors.
In cases of relapsing retinitis, it might be wise to change the treatment, especially if time to relapse has been short, suggesting a lesser sensitivity of the virus. It has been demonstrated that a combination of foscamet and ganciclovir was more effective in halting progression of CMV retinitis in patients with multiple CMV retinitis episodes.29
Local therapy, mainly with intravitreal implants, may be used in the absence of systemic CMV disease.
CMV prophylaxis
The ideal management of any infectious disease is a preventive strategy, particularly in infections with severe morbidity. Therefore, Overall these data suggest that the prophylactic role of CMV is far from being optimal and, given the benefit-risk ratio, it appears necessary to better define the population of HIV infected patients who might benefit the most from prophylaxis. Interestingly, in study 1654, the 
